The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy

Author(s): Nannan Ao, Qianping Chen, Geng Liu*

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 20 , Issue 5 , 2017

Become EABM
Become Reviewer
Call for Editor


Background & Aim: The ubiquitin-proteasome system (UPS) is the major pathway for degrading the intracellular proteins. The 2004 Nobel Prize in Chemistry was awarded to Rose, Hershko, and Ciechanover to highlight the fundamental importance of UPS.

Method & Results: The alterations in this process have been shown to contribute to the cancer progression. Hence, UPS has become a popular target for developing chemotherapeutics against tumours. The application of bortezomib showed high efficiency in treating haematological malignancies by interfering with UPS activity. Many compounds are being screened and evaluated in recent pharmacological advances, either as single agents or in synergy with other drugs, and more to be revealed.

Conclusion: In the present review, we exhibit the crucial ingredients involved in UPS and discuss the current situation of small molecules targeting various components of ubiquitination pathway in cancer treatment.

Keywords: Ubiquitin, cancer, small molecule inhibitors, proteasome, E3 ligase, deubiquitinating enzyme.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 07 September, 2017
Page: [403 - 413]
Pages: 11
DOI: 10.2174/1386207320666170710124746
Price: $65

Article Metrics

PDF: 47
HTML: 10
PRC: 1